Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,583.39
(
-0.62%
)
US TECH 100
23,616.80
(
-0.75%
)
Dow Jones
45,875.49
(
-0.76%
)
Brent Oil
107.61
(
0.96%
)
Bitcoin
69,258.15
(
-2.78%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 141660

Wednesday, 05/09/2012 7:11:15 PM

Wednesday, May 09, 2012 7:11:15 PM

Post# of 257259
ABT closed -2.2% on the Tofacitinib panel endorsement, a big daily move for this stock, while PFE finished +1.1%. In terms of the enterprise-value delta from today’s news, ABT lost slightly more than PFE gained, which is somewhat inefficient insofar as ABT is not the only company who stands to lose from Tofacitinib’s success.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now